These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17084858)

  • 41. Induction of covalent binding antibodies.
    Armentano F; Knight T; Makker S; Tramontano A
    Immunol Lett; 2006 Feb; 103(1):51-7. PubMed ID: 16297987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Production and characterization of anti-cocaine catalytic antibodies.
    de Prada P; Landry DW
    Methods Mol Biol; 2004; 248():495-501. PubMed ID: 14970516
    [No Abstract]   [Full Text] [Related]  

  • 43. Transition state docking: a probe for noncovalent catalysis in biological systems. Application to antibody-catalyzed ester hydrolysis.
    Tantillo DJ; Houk KN
    J Comput Chem; 2002 Jan; 23(1):84-95. PubMed ID: 11913392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crossreactivity, efficiency and catalytic specificity of an esterase-like antibody.
    Gigant B; Charbonnier JB; Eshhar Z; Green BS; Knossow M
    J Mol Biol; 1998 Dec; 284(3):741-50. PubMed ID: 9826512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isoabzymes: structurally and mechanistically similar catalytic antibodies from the same immunization.
    Angeles TS; Smith RG; Darsley MJ; Sugasawara R; Sanchez RI; Kenten J; Schultz PG; Martin MT
    Biochemistry; 1993 Nov; 32(45):12128-35. PubMed ID: 8218291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expanding the 43C9 class of catalytic antibodies using a chain-shuffling approach.
    Miller GP; Posner BA; Benkovic SJ
    Bioorg Med Chem; 1997 Mar; 5(3):581-90. PubMed ID: 9113336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Catalytic antibodies: generation of a new class of protein catalysts exploiting the immune system].
    Fujii I
    Yakugaku Zasshi; 1996 Aug; 116(8):606-21. PubMed ID: 8831262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generation, characterization, and docking studies of DNA-hydrolyzing recombinant F(ab) antibodies.
    Zein HS; El-Sehemy AA; Fares MO; ElHefnawi M; da Silva JA; Miyatake K
    J Mol Recognit; 2011; 24(5):862-74. PubMed ID: 21812061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and characterization of a humanized cocaine-binding antibody.
    Redwan el-RM; Larsen NA; Zhou B; Wirsching P; Janda KD; Wilson IA
    Biotechnol Bioeng; 2003 Jun; 82(5):612-8. PubMed ID: 12652485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diphtheria toxoid.
    Basmadjian GP; Singh S; Sastrodjojo B; Smith BT; Avor KS; Chang F; Mills SL; Seale TW
    Chem Pharm Bull (Tokyo); 1995 Nov; 43(11):1902-11. PubMed ID: 8575031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of putative active-site residues in the DNase domain of colicin E9 by random mutagenesis.
    Garinot-Schneider C; Pommer AJ; Moore GR; Kleanthous C; James R
    J Mol Biol; 1996 Aug; 260(5):731-42. PubMed ID: 8709151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selection and characterization of lipase abzyme from phage displayed antibody libraries.
    Leong MK; Chen C; Shar KC; Shiuan D
    Biochem Biophys Res Commun; 2007 Sep; 361(3):567-73. PubMed ID: 17673171
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thermodynamic and structural basis for transition-state stabilization in antibody-catalyzed hydrolysis.
    Oda M; Ito N; Tsumuraya T; Suzuki K; Sakakura M; Fujii I
    J Mol Biol; 2007 May; 369(1):198-209. PubMed ID: 17428500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
    Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
    Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres.
    Homayoun P; Mandal T; Landry D; Komiskey H
    J Pharm Pharmacol; 2003 Jul; 55(7):933-8. PubMed ID: 12906750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Catalytic antibody light chain capable of cleaving a chemokine receptor CCR-5 peptide with a high reaction rate constant.
    Mitsuda Y; Hifumi E; Tsuruhata K; Fujinami H; Yamamoto N; Uda T
    Biotechnol Bioeng; 2004 Apr; 86(2):217-25. PubMed ID: 15052642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Catalytic antibodies and their applications.
    Hanson CV; Nishiyama Y; Paul S
    Curr Opin Biotechnol; 2005 Dec; 16(6):631-6. PubMed ID: 16243512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A catalytic antibody that accelerates the hydrolysis of carbonate esters. Prediction of the binding-site structure of the substrate.
    Suzuki H; Mukouyama EB; Wada C; Kawamura-Konishi Y; Wada Y; Ono M
    J Protein Chem; 1998 Apr; 17(3):273-8. PubMed ID: 9588951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Catalytic antibodies induced by a zwitterionic hapten.
    Tsumuraya T; Takazawa N; Tsunakawa A; Fleck R; Masamune S
    Chemistry; 2001 Sep; 7(17):3748-55. PubMed ID: 11575776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction.
    Zheng F; Zhan CG
    Org Biomol Chem; 2008 Mar; 6(5):836-43. PubMed ID: 18292872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.